Amphiphilic Oligomers: A New Kind of Macromolecular Carrier of Antimitotic Drugs

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Amphiphilic Oligomers: A New Kind of Macromolecular Carrier of Antimitotic Drugs

Anti-Cancer Agents in Medicinal Chemistry, 2(6): 645-665.

Author(s): Christiane Contino-Pepin, Jean Claude Maurizis and Bernard Pucci.

Affiliation: Universite d'Avignon, Laboratoire de Chimie Bioorganique et des Systemes Moleculaires Vectoriels, 33 rue Louis Pasteur, 84000 - Avignon, France.


The last three decades have seen the development of new concepts in the biomedical and medical field based on the principle of drug carrying and in vivo pharmaco-targeting using synthetic carriers such as nanoparticles, liposomes or polymers. This review deals with the synthesis and biomedical applications of a new kind of macromolecular compounds: end-capped oligomers called telomers. The telomers, derived from Tris(hydroxymethyl)aminomethane bearing either a hydro- or a fluorocarbon tail, are described. Their functionality and biocompatibility enhance their potential in the biomedical and medical fields. Such compounds exhibit no cytotoxicity and are able to cross cell membranes by endocytosis. After i.v or per os administration in the animal, they exhibit a very good bio-avaibility and a homogeneous distribution in all tissues without any accumulation. Their ability to carry in vivo antimitotic drugs has been shown. Moreover, the grafting of different glycoside moieties onto the hydroxyl groups of telomers allows the selective targeting of specific receptors called integrins. Finally, we have shown the potential use of telomers bearing specific peptide ligands, such as RGD sequences, in the selective carrying of antimitotic drugs to the angiogenic zone surrounding tumors.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 2
Issue Number: 6
First Page: 645
Last Page: 665
Page Count: 21
DOI: 10.2174/1568011023353732
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science